Answers are grounded in this paper and cite their sources.
Background: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. Clinical practice guidelines recommend risk-stratified prophylactic G-CSF therapy, which is indicated primarily for patients with a high risk of febrile neutropenia (FN >20%).Although G-CSF is widely used in clinical practice in China, it remains unclear whether this use aligns with guideline-recommended risk stratification, as few real-world studies have evaluated adherence. Objectives: This study aimed to evaluate the appropriateness of prophylactic G-CSF use in hospitalized breast cancer patients and identify the gap between clinical practice and current guidelines. Methods: In this single-center, retrospective observational study, we evaluated the prophylactic use of G-CSF according to FN risk category among breast cancer patients scheduled to receive myelosuppressive chemotherapy in hospitalized patients in China between January 2019 and December 2021. Results: A total of 4,181 chemotherapy cycles from 630 breast cancer patients were documented. The overall rate of prophylactic G-CSF use was 53.1%. Among these, 1,963 cycles (46.9%) involved inappropriate prophylactic use, including 1,836 cycles (43.9%) with underuse, 101 cycles (2.4%) with overuse and 26 cycles (0.6%) with non-standard use. Conclusion: This study reveals substantial inappropriate use of prophylactic G-CSF in Chinese breast cancer patients, primarily characterized by underuse in guideline-indicated scenarios.
No takes yet. Share an insight, caveat, or question.
Lilian Hu (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: